Skip to main content

Clinuvel Pharmaceuticals (AU:CUV) — Company Overview, News & Financial Data

Clinuvel Pharmaceuticals logo
CUVClinuvel Pharmaceuticals
A doctor examining light-based diagnostic equipment near a window with soft golden sunlight streaming across skin-toned photographic samples.
Company profile

Clinuvel Pharmaceuticals

About

Explore Australia companies

Clinuvel Pharmaceuticals (ASX:CUV) is an Australian biopharmaceutical company that develops and commercialises novel phototherapeutic drugs to treat and protect people with genetic photosensitivity disorders. The company's flagship product, Scenesse®, is a prescription drug for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe pain and burning sensations in the skin when exposed to sunlight.

Snapshot

Public AUOwnership
1987Year founded
64Employees
Victoria, AustraliaHead office
Loading Map...
Global footprint

Operations

All Locations
Australia

Products and/or services of Clinuvel Pharmaceuticals

  • Development of novel photoprotective drugs: Clinuvel Pharmaceuticals is a specialty pharmaceutical company focused on developing novel photoprotective drugs for the prevention and treatment of light-related skin disorders.
  • Commercialization of Scenesse: Scenesse is Clinuvel Pharmaceuticals' flagship product, a prescription oral medication that helps to protect patients with genetic photosensitivity disorders from the harmful effects of ultraviolet (UV) radiation.
  • Research and development of new drugs and treatments: Clinuvel Pharmaceuticals is actively researching and developing new drugs and treatments for a range of light-related skin disorders, including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma.
  • Clinical trials of new drugs and treatments: Clinuvel Pharmaceuticals is conducting a number of clinical trials of new drugs and treatments for light-related skin disorders.
  • Manufacturing and distribution of Scenesse: Clinuvel Pharmaceuticals manufactures and distributes Scenesse to patients around the world.

Clinuvel Pharmaceuticals executive team

  • Dr. Philippe Jacques Wolgen M.B.A., M.D.CEO, MD & Director
  • Mr. Peter VaughanChief Financial Officer
  • Mr. Lachlan HayChief Operations Officer
  • Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Chief Scientific Officer
  • Mr. Malcolm BullHead of Australian Operations & Investor Relations
  • Dr. Azza HamilaHead of Quality Assurance & Drug Safety
  • Mr. David SolomonHead of Regulatory Affairs
  • Ms. Claire Newstead-Sinclair C.A.Company Secretary